GeneDx Holdings Corp. (WGS) Revenue History
Annual and quarterly revenue from 2020 to present
WGS Revenue Over Time (2020–2025)
WGS Revenue Growth History
4 of 5 years with positive growth- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- +18.3%
- FY2022 revenue growth
- +10.6%
- FY2023 revenue growth
- -13.7%
- FY2024 revenue growth
- +50.8%
- FY2025 revenue growth
- +40.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $102.3M | +17.4% |
| Q4 2025 | $121.0M | +26.5% |
| Q3 2025 | $116.7M | +51.9% |
| Q2 2025 | $102.7M | +45.6% |
| Q1 2025 | $87.1M | +39.6% |
| Q4 2024 | $95.6M | +66.6% |
| Q3 2024 | $76.9M | +44.2% |
| Q2 2024 | $70.5M | +44.8% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
WGS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
WGS Revenue Analysis (2020–2025)
Current Revenue & Growth
As of June 28, 2026, GeneDx Holdings Corp. (WGS) generated trailing twelve-month (TTM) revenue of $442.7 million, reflecting strong growth of +17.4% year-over-year. The most recent quarter (Q1 2026) recorded $102.3 million in revenue, down 15.5% sequentially.
Historical Growth Trajectory
WGS's 5-year compound annual growth rate (CAGR) stands at +19.0%, indicating consistent double-digit revenue growth. The 3-year CAGR of +22.1% exceeds the 5-year average, indicating an acceleration in the most recent period. GeneDx Holdings Corp.'s highest annual revenue of $427.5 million was recorded in 2025, an all-time high.
Revenue by Segment
WGS's revenue is primarily driven by Diagnostic Test (49%), Diagnostic Test, Third Party Insurance (41%), and Diagnostic Test, Institutional Customers (8%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including PACB (+5.0% YoY), NTRA (+36.6% YoY), and EXAS (+17.7% YoY) — WGS has outperformed the peer group in revenue growth. Compare WGS vs PACB →
WGS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| WGSCurrent | $443M | +17.4% | +19.0% | -2.8% | |
 PACB | $160M | +5.0% | +15.2% | -348.5% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
WGS Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $427.5M | +40.0% | $298.2M | 69.7% | $-11,802,000 | -2.8% |
| 2024 | $305.4M | +50.8% | $194.4M | 63.6% | $-23,213,000 | -7.6% |
| 2023 | $202.6M | -13.7% | $90.0M | 44.4% | $-180,596,000 | -89.2% |
| 2022 | $234.7M | +10.6% | $-26,750,000 | -11.4% | $-667,652,000 | -284.5% |
| 2021 | $212.2M | +18.3% | $-16,602,000 | -7.8% | $-446,149,000 | -210.3% |
| 2020 | $179.3M | - | $4.0M | 2.2% | $-241,994,000 | -134.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
WGS — Frequently Asked Questions
Quick answers to the most common questions about buying WGS stock.
Is WGS's revenue growth accelerating or slowing?
WGS revenue growth is accelerating. TTM revenue reached $443M, up +17.4% year-over-year — ahead of the 5-year CAGR of +19.0%. This indicates the business is expanding faster than its historical baseline.
What is WGS's revenue history from 2020 to 2026?
GeneDx Holdings Corp. (WGS) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $443M, growing at +17.4% YoY. The 5-year CAGR is +19.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is WGS's long-term revenue growth rate (CAGR)?
GeneDx Holdings Corp.'s 5-year revenue CAGR of +19.0% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +17.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for WGS.
Why does WGS's quarterly revenue fluctuate?
WGS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. GeneDx Holdings Corp.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is WGS's revenue distributed by segment?
WGS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does WGS's revenue compare to industry peers?
GeneDx Holdings Corp. (WGS) with TTM revenue of $443M and +17.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.